返回
摘要
En 中文
Expectant management of a cesarean scar pregnancy (CSP) is associated with a high risk of severe maternal morbidity. Therefore, most experts recommend immediate termination after the diagnosis of a CSP. However, there is no consensus about the optimal management of a CSP in terms of efficacy, safety, and preservation of future fertility. Methotrexate (MTX) is a folic acid antagonist that has been largely used to treat tubal ectopic pregnancies. This review summarizes the current knowledge and uncertainties about the administration of MTX as a medical or noninvasive option to terminate a CSP; the preferred injection route (systemic or local/intragestational), the comparison with other treatment modalities, and the prognostic factors for MTX success will be discussed, as well as the recommendations from scientific societies. & COPY; 2023 Published by Elsevier Ltd.
Keyword:
Cesarean scar pregnancy
Treatment
Methotrexate
Systemic
Local
Intragestational
期刊
B
IF:
4.1
论文数:
2.0K
被引数:
7.3K
机构
引用论文
Society for Maternal-Fetal Medicine Consult Series #63: Cesarean scar ectopic pregnancy母胎医学学会咨询系列 #63: 剖宫产瘢痕异位妊娠
Definition and sonographic reporting system for Cesarean scar pregnancy in early gestation: modified Delphi method妊娠早期剖宫产瘢痕妊娠的定义及超声报告系统: 改良Delphi法

